Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Documenti analoghi

• Effect of Direct‐Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan
  di: Hironori Ochi, et al.
  Pubblicazione: (2026)
• Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group
  di: Keiji Tsuji, et al.
  Pubblicazione: (2025)
• Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2025)
• Impact of immune‐related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
  di: Keito Suzuki, et al.
  Pubblicazione: (2024)